Correction (DOI:10.1016/j.cgh.2006.02.002);Chronic Hepatitis C in Patients With Persistently Normal Alanine Transaminase Levels

Clinical Gastroenterology and Hepatology

Volumn 4, Issue 5, 2006, Pages 645-652

  Shiffman, Mitchell L ^a   Diago, Moisés ^b   Tran, Albert ^c   Pockros, Paul ^d   Reindollar, Robert ^e   Prati, Daniele ^f,g   Rodríguez Torres, Maribel ^h   Lardelli, Pilar ⁱ   Blotner, Steven ^j   Zeuzem, Stefan ^k  

^a VIRGINIA COMMONWEALTH UNIVERSITY MEDICAL CENTER   (United States)

^b HOSPITAL GENERAL UNIVERSITARIO DE VALENCIA   (Spain)

^c CENTRE HOSPITALIER UNIVERSITAIRE DE NICE   (France)

^d SCRIPPS CLINIC   (United States)

^e Carolinas Center for Liver Disease   (United States)

^f FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

^g A MANZONI HOSPITAL   (Italy)

^h Fundacion de Investigacion de Diego Santurce   (Puerto Rico)

ⁱ F HOFFMANN LA ROCHE LTD   (Switzerland)

^j HOFFMANN LA ROCHE INC   (United States)

^k SAARLAND UNIVERSITY   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; PEGINTERFERON ALPHA2A; RNA;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CORRELATION ANALYSIS; FEMALE; FOLLOW UP; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LIVER BIOPSY; LIVER DISEASE; LIVER FIBROSIS; LIVER HISTOLOGY; MAJOR CLINICAL STUDY; MALE; NONHUMAN; TIME SERIES ANALYSIS;

EID: 33646121757     PISSN: 15423565     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cgh.2006.06.018     Document Type: Erratum

References (31)

1. Bacon B.R. Treatment of patients with hepatitis C and normal serum aminotransferase levels. Hepatology 36 Suppl 1 (2002) S179-S184
2. Ahmed A., and Keeffe E.B. Chronic hepatitis C with normal aminotransferase levels. Gastroenterology 126 (2004) 1409-1415
3. Alberti A., Noventa F., Benvegnù L., et al. Prevalence of liver disease in a population of asymptomatic persons with hepatitis C virus infection. Ann Intern Med 137 (2002) 961-964
4. Puoti C., Magrini A., Stati T., et al. Clinical, histological, and virological features of hepatitis C virus carriers with persistently normal or abnormal alanine transaminase levels. Hepatology 26 (1997) 1393-1398
5. Shiffman M.L., Stewart C.A., Hofmann C.M., et al. Chronic infection with hepatitis C virus in patients with elevated or persistently normal serum alanine aminotransferase levels. comparison of hepatic histology and response to interferon therapy. J Infect Dis 182 (2000) 1595-1601
6. Jamal M.M., Soni A., Quinn P.G., et al. Clinical features of hepatitis C-infected patients with persistently normal alanine transaminase levels in the southwestern United States. Hepatology 30 (1999) 1307-1311
7. Herve S., Savoye G., Riachi G., et al. Chronic hepatitis C with normal or abnormal aminotransferase levels. is it the same entity?. Eur J Gastroenterol Hepatol 13 (2001) 495-500
8. Puoti C., Castellacci R., Montagnese F., et al. Histological and virological features and follow-up of hepatitis C virus carriers with normal aminotransferase levels. the Italian prospective study of the asymptomatic C carriers (ISACC). J Hepatol 37 (2002) 117-123
9. Martinot-Peignoux M., Boyer N., Cazals-Hatem D., et al. Prospective study on anti-hepatitis C virus-positive patients with persistently normal serum alanine transaminase with or without detectable serum hepatitis C virus RNA. Hepatology 34 (2001) 1000-1005
10. Tsuji K., Yamasaki K., Yamanishi M., et al. Risk of alanine aminotransferase flare-up among asymptomatic hepatitis C virus RNA carriers. a 10-year follow-up study. J Gastroenterol Hepatol 16 (2001) 536-540
11. Serfaty L., Chazouilleres O., Pawlotsky J.M., et al. Interferon alfa therapy in patients with chronic hepatitis C and persistently normal aminotransferase activity. Gastroenterology 110 (1996) 291-295
12. Rossini A., Ravaggi A., Biasi L., et al. Virological response to interferon treatment in hepatitis C virus carriers with normal aminotransferase levels and chronic hepatitis. Hepatology 26 (1997) 1012-1017
13. Orito E., Mizokami M., Suzuki K., et al. Interferon-alpha therapy for individuals with normal serum alanine aminotransferase levels before treatment. J Gastroenterol Hepatol 12 (1997) 58-61
14. Marcellin P., Levy S., and Erlinger S. Therapy of hepatitis C. patients with normal aminotransferase levels. Hepatology 26 (1997) 133S-136S
15. Zeuzem S., Diago M., Gane E., et al. Peginterferon alfa-2a (40KD) and ribavirin in patients with normal aminotransferase levels. Gastroenterology 127 (2004) 1724-1732
16. Prati D., Taioli E., Zanella A., et al. Updated definitions of healthy ranges for serum alanine aminotransferase levels. Ann Intern Med 137 (2002) 1-10
17. Fried M.W., Shiffman M.L., Reddy K.R., et al. Combination of peginterferon alfa-2a plus ribavirin in patients with chronic hepatitis C virus infection. N Engl J Med 347 (2002) 975-982
18. Hadziyannis S.J., Sette H., Morgan T.R., et al. Peginterferon alfa-2a and ribavirin combination therapy in chronic hepatitis C. A randomized study of treatment duration and ribavirin dose. Ann Intern Med 140 (2004) 370-381
19. Knodell R.G., Ishak K.G., Black W.C., et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1 (1981) 431-435
20. Pearson W.H. Estimation of a correlation coefficient from an uncertainty measure. Psychometrika 31 (1966) 421-433
21. Mathurin P., Moussalli J., Cadranel J.F., et al. Slow progression rate of fibrosis in hepatitis C virus patients with persistently normal alanine transaminase activity. Hepatology 27 (1998) 868-872
22. Poynard T., Bedossa P., Opolon P., The OBSVIRC, METAVIR, CLINIVIR, and and DOSVIRC groups. Natural history of liver fibrosis progression in patients with chronic hepatitis C. Lancet 349 (1997) 825-832
23. Piton A., Poynard T., Imber-Bismut F., et al., MULTIVIRC Group. Factors associated with serum alanine transaminase activity in healthy subjects. consequences for the definition of normal values, for selection of blood donors, and for patients with chronic hepatitis C. Hepatology 27 (1998) 1213-1219
24. Sakugawa H., Nakasone H., Nakayoshi T., et al. Alanine aminotransferase (ALT) levels in a normal population and interferon therapy in chronic hepatitis C patients with normal ALT. Hepatogastroenterology 50 (2003) 165-169
25. Silini E., Bono F., Cividini A., et al. Differential distribution of hepatitis C virus genotypes in patients with and without liver function abnormalities. Hepatology 21 (1995) 285-290
26. Prati D., Capelli C., Zanella A., et al. Influence of different hepatitis C virus genotypes on the course of asymptomatic hepatitis C virus infection. Gastroenterology 110 (1996) 178-183
27. Dincer D., Okten A., Kaymakoglu S., et al. Persistently normal alanine transaminase levels in chronic C hepatitis. what does it tell us?. Hepatogastroenterology 48 (2001) 1397-1400
28. Rumi M.G., De Filippi F., Donato M.F., et al. Progressive hepatic fibrosis in healthy carriers of hepatitis C virus with a transaminase breakthrough. J Viral Hepat 9 (2002) 71-74
29. Hornberger J, Farci P, Prati D, et al. The economics of treating chronic hepatitis C patients with peginterferon alfa 2a (40KD) plus ribavirin presenting with persistently normal aminotransferase. J Viral Hepat 2006 (in press).
30. National Institutes of Health. Consensus development conference statement: management of hepatitis C: 2002-June 10-12, 2002. Hepatology 36 Suppl 1 (2002) S3-S20
31. Strader D.B., Wright T., Thomas D.L., et al. Diagnosis, management, and treatment of hepatitis C. Hepatology 39 (2004) 1147-1171